Anthem Biosciences Reports Stellar Q1 FY26 Performance with Robust Growth Across Metrics.

Anthem Biosciences delivered an outstanding set of numbers for the June 2025 quarter, showcasing strong revenue growth and a sharp rise in profitability. Sales surged 60% YoY to ₹540 crore from ₹339 crore in June 2024, supported by higher demand across its product portfolio. EBIDT rose 58% YoY to ₹191 crore from ₹121 crore, reflecting operational efficiency and healthy margins. Net profit jumped 65% YoY to ₹136 crore from ₹82.4 crore, while EPS climbed 65% to ₹2.42 from ₹1.47, highlighting strong earnings momentum. At a market price of ₹808 and a market cap of ₹45,378 crore, the stock trades at a PE of 100.5, factoring in expectations of sustained growth in the specialty chemicals and pharma segments. In the end, Anthem Biosciences has delivered another quarter of high double-digit growth in both revenue and profits, indicating strong execution and demand momentum as FY26 unfolds.